237 related articles for article (PubMed ID: 20421814)
21. Three-dimensional evaluation of chemotherapy response in malignant pleural mesothelioma.
Ak G; Metintas M; Metintas S; Yildirim H; Ozkan R; Ozden H
Eur J Radiol; 2010 Apr; 74(1):130-5. PubMed ID: 19268516
[TBL] [Abstract][Full Text] [Related]
22. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans.
Francis RJ; Byrne MJ; van der Schaaf AA; Boucek JA; Nowak AK; Phillips M; Price R; Patrikeos AP; Musk AW; Millward MJ
J Nucl Med; 2007 Sep; 48(9):1449-58. PubMed ID: 17704250
[TBL] [Abstract][Full Text] [Related]
23. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
[TBL] [Abstract][Full Text] [Related]
24. Positron emission tomography predicts survival in malignant pleural mesothelioma.
Flores RM; Akhurst T; Gonen M; Zakowski M; Dycoco J; Larson SM; Rusch VW
J Thorac Cardiovasc Surg; 2006 Oct; 132(4):763-8. PubMed ID: 17000285
[TBL] [Abstract][Full Text] [Related]
25. Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma.
Lang-Lazdunski L; Bille A; Lal R; Cane P; McLean E; Landau D; Steele J; Spicer J
J Thorac Oncol; 2012 Apr; 7(4):737-43. PubMed ID: 22425923
[TBL] [Abstract][Full Text] [Related]
26. The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma.
Proto C; Signorelli D; Mallone S; Prelaj A; Lo Russo G; Imbimbo M; Galli G; Ferrara R; Ganzinelli M; Leuzzi G; Greco FG; Calareso G; Botta L; Gatta G; Garassino M; Trama A
Clin Lung Cancer; 2019 Nov; 20(6):e652-e660. PubMed ID: 31377142
[TBL] [Abstract][Full Text] [Related]
27. A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
Kataoka Y; Yamamoto Y; Otsuki T; Shinomiya M; Terada T; Fukuma S; Yamazaki S; Hirabayashi M; Nakano T; Fukuhara S
Jpn J Clin Oncol; 2015 Jun; 45(6):562-8. PubMed ID: 25838292
[TBL] [Abstract][Full Text] [Related]
28. Trimodality Treatment of Malignant Pleural Mesothelioma: An Institutional Review.
Kapeles M; Gensheimer MF; Mart DA; Sottero TL; Kusano AS; Truong A; Farjah F; Laramore GE; Stelzer KJ; Patel SA
Am J Clin Oncol; 2018 Jan; 41(1):30-35. PubMed ID: 26353120
[TBL] [Abstract][Full Text] [Related]
29. Prognostic factors according to the treatment schedule in malignant pleural mesothelioma.
Ak G; Metintas S; Metintas M; Yildirim H; Erginel S; Kurt E; Alatas F; Cadirci O
J Thorac Oncol; 2009 Nov; 4(11):1425-30. PubMed ID: 19752758
[TBL] [Abstract][Full Text] [Related]
30. Complete response and long-term survival in malignant pleural mesothelioma: case report.
Takanen S; Resuli B; Graziano V; Parisi A; Lisi R; Raffetto N; Tombolini V
Anticancer Res; 2012 Apr; 32(4):1485-7. PubMed ID: 22493390
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factors for 100 patients with malignant pleural mesothelioma.
Gonlugur U; Gonlugur TE
Arch Environ Occup Health; 2010; 65(2):65-9. PubMed ID: 20439224
[TBL] [Abstract][Full Text] [Related]
32. [Long-term prognostic analysis of patients with malignant pleural mesothelioma].
Cao KJ; Cui NJ
Ai Zheng; 2005 Jan; 24(1):72-5. PubMed ID: 15642204
[TBL] [Abstract][Full Text] [Related]
33. Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma.
Neragi-Miandoab S; Richards WG; Sugarbaker DJ
Int J Surg; 2008 Aug; 6(4):293-7. PubMed ID: 18585112
[TBL] [Abstract][Full Text] [Related]
34. Prognostic importance of volumetric measurements in stage I lung adenocarcinoma.
Yanagawa M; Tanaka Y; Leung AN; Morii E; Kusumoto M; Watanabe S; Watanabe H; Inoue M; Okumura M; Gyobu T; Ueda K; Honda O; Sumikawa H; Johkoh T; Tomiyama N
Radiology; 2014 Aug; 272(2):557-67. PubMed ID: 24708191
[TBL] [Abstract][Full Text] [Related]
35. Induction of apoptosis by intrapleural perfusion hyperthermo-chemotherapy for malignant pleural mesothelioma.
Matsuzaki Y; Tomita M; Shimizu T; Hara M; Ayabe T; Onitsuka T
Ann Thorac Cardiovasc Surg; 2008 Jun; 14(3):161-5. PubMed ID: 18577894
[TBL] [Abstract][Full Text] [Related]
36. The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: implications for revision of the American Joint Committee on Cancer staging system.
Flores RM; Routledge T; Seshan VE; Dycoco J; Zakowski M; Hirth Y; Rusch VW
J Thorac Cardiovasc Surg; 2008 Sep; 136(3):605-10. PubMed ID: 18805259
[TBL] [Abstract][Full Text] [Related]
37. A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters.
Nowak AK; Francis RJ; Phillips MJ; Millward MJ; van der Schaaf AA; Boucek J; Musk AW; McCoy MJ; Segal A; Robins P; Byrne MJ
Clin Cancer Res; 2010 Apr; 16(8):2409-17. PubMed ID: 20371686
[TBL] [Abstract][Full Text] [Related]
38. Quantitative Clinical Staging for Patients With Malignant Pleural Mesothelioma.
Gill RR; Yeap BY; Bueno R; Richards WG
J Natl Cancer Inst; 2018 Mar; 110(3):258-264. PubMed ID: 29931180
[TBL] [Abstract][Full Text] [Related]
39. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center.
Flores RM; Zakowski M; Venkatraman E; Krug L; Rosenzweig K; Dycoco J; Lee C; Yeoh C; Bains M; Rusch V
J Thorac Oncol; 2007 Oct; 2(10):957-65. PubMed ID: 17909360
[TBL] [Abstract][Full Text] [Related]
40. Is pleurectomy and decortication superior to palliative care in the treatment of malignant pleural mesothelioma?
Zahid I; Sharif S; Routledge T; Scarci M
Interact Cardiovasc Thorac Surg; 2011 May; 12(5):812-7. PubMed ID: 21345818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
